Adaptive Biotechnologies CFO trades 4,290 ADPT shares

Adaptive Biotechnologies Corp Chief Financial Officer Kyle Piskel reported an option exercise and share sale in company stock.

Rhea-AI Filing Summary

Adaptive Biotechnologies Corp Chief Financial Officer Kyle Piskel reported an option exercise and share sale in company stock. On January 12, 2026, he exercised stock options for 4,290 shares of common stock at an exercise price of $12.14 per share, receiving 4,290 shares.

On the same date, he sold 4,290 shares of common stock at a price of $18 per share, leaving him with 216,637 shares of common stock held directly after the transactions. The filing notes these trades were carried out under a Rule 10b5-1 trading plan adopted on August 28, 2025. Following the exercise, 4,291 stock options remained beneficially owned.

Insider Trade Summary

Exercise and Sale: 4,290 shares ($25K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider PISKEL KYLE

Role Chief Financial Officer

Sold 4,290 shs ($77K)

Approx. gross sale proceeds $77K

Approx. exercise cost $52K

Approx. pre-tax spread $25K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	4,290	$0.00	$0.00
Exercise	Common Stock	4,290	$12.14	$52K
Sale	Common Stock	4,290	$18.00	$77K

Holdings After Transaction: Stock Option (right to buy) — 4,291 contracts (Direct); Common Stock — 216,637 shares (Direct)

Footnotes (2)

1. F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 28, 2025.
2. F2. The options vested with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did ADPT's CFO report on this Form 4?

On January 12, 2026, ADPT Chief Financial Officer Kyle Piskel exercised stock options for 4,290 shares of common stock at $12.14 per share and sold 4,290 shares of common stock at $18 per share.

How many Adaptive Biotechnologies (ADPT) shares does the CFO own after these trades?

After the reported transactions, Chief Financial Officer Kyle Piskel beneficially owns 216,637 shares of Adaptive Biotechnologies common stock held directly.

Were the ADPT CFO’s trades made under a Rule 10b5-1 trading plan?

Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan adopted by the reporting person on August 28, 2025.

What stock options did the ADPT CFO exercise in this Form 4?

He exercised a stock option (right to buy) for 4,290 shares of common stock at an exercise price of $12.14 per share, leaving 4,291 stock options beneficially owned afterward.

How do the ADPT CFO’s options vest according to the filing?

The options vested as follows: 1/4 of the shares vested on March 4, 2023, with 1/48 of the shares vesting each full month of continuous service thereafter until fully vested.

What is the CFO’s role and relationship to Adaptive Biotechnologies (ADPT)?

The reporting person, Kyle Piskel, is listed as an officer of Adaptive Biotechnologies Corp, serving as its Chief Financial Officer, and files the Form 4 as a single reporting person.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/14/2026 - 07:17 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PISKEL KYLE

(Last) (First) (Middle)

C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION

1165 EASTLAKE AVE E

(Street)

SEATTLE WA 98109

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Adaptive Biotechnologies Corp [ ADPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/12/2026		M(1)		4,290	A	$12.14	220,927	D
Common Stock	01/12/2026		S(1)		4,290	D	$18	216,637	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$12.14	01/12/2026		M(1)			4,290	(2)	03/04/2032	Common Stock	4,290	$0	4,291	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 28, 2025.

2. The options vested with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

	/s/ Kyle Piskel	01/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.